SINGAPORE, Oct. 25 /Xinhua-PRNewswire/ -- NanoMaterials Technology ("NMT") announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.
As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.
"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.
NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").
John Mitchell retired from Pfizer Inc as Senior Vice President and President/Team Leader, Pfizer Global Manufacturing at the end of 2004. While at Pfizer, he was responsible for worldwide manufacturing operations that produced pharmaceutical, consumer healthcare and animal health products, encompassing plants and logistics centers at more than 120 sites in 40 countries.
John holds a Bachelor of Engineering degree from Yale University and an honorary Doctor of Laws degree from the National University of Ireland.
Prof. Neumann is currently a Senior Consultant of R&D at Merck KGaA. At
Merck KGaA, Prof. Neumann was a group leader in R&D in the Diagnostic
Division until 1985. He subsequently headed up the Immunochemistry
Department in Preclinical Research at Merck Pharma until 1989 when he
returned as the Head of R&D of the Diagnostic Division. In 1994, he moved
on to head up the Business Development and Research Alliance Office in
Specialty Chemistry and Bio
|SOURCE NanoMaterials Technology Pte Ltd|
Copyright©2007 PR Newswire.
All rights reserved